Innovation Pharmaceuticals Inc (IPIX)

[mdphd2008]

Had a quick thought regarding another potential use for Brilacidin in GI marketplace to potentially treat clostridium dificile based on its antibiotic and immunomodulatory properties.

Taken from Wikipedia:

Clostridium difficile infection (CDI) is a symptomatic infection due to the spore-forming bacterium, Clostridium difficile. Symptoms include watery diarrhea, fever, nausea, and abdominal pain. Complications may include pseudomembranous colitis, toxic megacolon, perforation of the colon, and sepsis.

Often the antibiotics metronidazole, vancomycin or fidaxomicin will cure the infection.

C. difficile has become the most common microbial cause of healthcare-associated infections in U.S. hospitals and costs up to $4.8 billion each year in excess health care costs for acute care facilities alone.

As mentioned above, vancomycin (usually in oral formulation) is often a common treatment choice.

If Brilacidin can be shown to be effective for this indication, this can be of further interest to a partner that is already marketing this to the GI market for UP/UC conditions.